These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 11461675)

  • 1. Improvement of HIV-specific immunity in HIV-infected twins treated with highly active antiretroviral therapy, interleukin 2, and syngeneic adoptively transferred cells.
    Tsoukas CM; Turner HM; Hatzakis GE; Blake GP; Goodhew JE; Kilby DL; Kovacs CM; Luetkehoelter JR; Routy JP; Walmsley SL; Bernard NF
    AIDS Res Hum Retroviruses; 2001 Jul; 17(10):887-900. PubMed ID: 11461675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adoptive transfer of syngeneic T cells in HIV-1 discordant twins indicates rapid regulation of T-cell homeostasis.
    Hoffmann C; Stellbrink HJ; Dielschneider T; Degen O; Stoehr A; Knechten H; Wolf E; van Lunzen J
    Br J Haematol; 2007 Feb; 136(4):641-8. PubMed ID: 17223918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pilot study of the effects of intermittent interleukin-2 on human immunodeficiency virus (HIV)-specific immune responses in patients treated during recently acquired HIV infection.
    Dybul M; Hidalgo B; Chun TW; Belson M; Migueles SA; Justement JS; Herpin B; Perry C; Hallahan CW; Davey RT; Metcalf JA; Connors M; Fauci AS
    J Infect Dis; 2002 Jan; 185(1):61-8. PubMed ID: 11756982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inconsistent reconstitution of cytomegalovirus-specific cell-mediated immunity in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy.
    Weinberg A; Wohl DA; Barrett RJ; van der Horst C
    J Infect Dis; 2001 Sep; 184(6):707-12. PubMed ID: 11517431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-1-infected children on HAART: immunologic features of three different levels of viral suppression.
    Zaccarelli-Filho CA; Ono E; Machado DM; Brunialti M; Succi RC; Salomão R; Kallás EG; de Moraes-Pinto MI
    Cytometry B Clin Cytom; 2007 Jan; 72(1):14-21. PubMed ID: 17041945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dysregulation of CD28 and CTLA-4 expression by CD4 T cells from previously immunodeficient HIV-infected patients with sustained virological responses to highly active antiretroviral therapy.
    Stone SF; Price P; French MA
    HIV Med; 2005 Jul; 6(4):278-83. PubMed ID: 16011533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Normalized CD8+ but not CD4+ lymphocyte IL-2 expression is associated with early treatment with highly active antiretroviral therapy.
    Akerele T; Galatowicz G; Bunce C; Calder V; Lynn WA; Lightman S
    Clin Immunol; 2006 Nov; 121(2):191-7. PubMed ID: 16987710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IMMUNOLOGICAL PROFILES IN HIV POSITIVE PATIENTS FOLLOWING HAART INITIATION IN KIGALI, RWANDA.
    Twizerimana AP; Mwatha J; Musabyimana JP; Kayigi E; Harelimana Jde D; Karanja SM; Mutesa L
    East Afr Med J; 2014 Aug; 91(8):261-6. PubMed ID: 26862650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Restoration of CD4 T-cell responses to cytomegalovirus is short-lived in severely immunodeficient HIV-infected patients responding to highly active antiretroviral therapy.
    Keane NM; Price P; Lee S; Almeida CA; Stone SF; James I; French MA
    HIV Med; 2004 Nov; 5(6):407-14. PubMed ID: 15544692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-2 therapy restores CD8 cell non-cytotoxic anti-HIV responses in primary infection subjects receiving HAART.
    Martinez-Mariño B; Shiboski S; Hecht FM; Kahn JO; Levy JA
    AIDS; 2004 Oct; 18(15):1991-9. PubMed ID: 15577620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunological and virological efficacy of a therapeutic immunization combined with interleukin-2 in chronically HIV-1 infected patients.
    Lévy Y; Gahéry-Ségard H; Durier C; Lascaux AS; Goujard C; Meiffrédy V; Rouzioux C; El Habib R; Beumont-Mauviel M; Guillet JG; Delfraissy JF; Aboulker JP;
    AIDS; 2005 Feb; 19(3):279-86. PubMed ID: 15718838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pilot study to assess inflammatory biomarker changes when raltegravir is added to a virologically suppressive HAART regimen in HIV-1-infected patients with limited immunological responses.
    Lichtenstein KA; Armon C; Nagabhushanam V; Efaw BJ; Frazer-Abel A; Hiserote ME; Alam R
    Antivir Ther; 2012; 17(7):1301-9. PubMed ID: 22948290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of antiretroviral therapies in mucocutaneous manifestations in HIV-infected children over a period of two decades.
    Seoane Reula E; Bellon JM; Gurbindo D; Muñoz-Fernandez MA
    Br J Dermatol; 2005 Aug; 153(2):382-9. PubMed ID: 16086754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Central memory CD4 T cells are associated with incomplete restoration of the CD4 T cell pool after treatment-induced long-term undetectable HIV viraemia.
    Rallón N; Sempere-Ortells JM; Soriano V; Benito JM
    J Antimicrob Chemother; 2013 Nov; 68(11):2616-25. PubMed ID: 23833186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose daily subcutaneous interleukin-2 in combination with highly active antiretroviral therapy in HIV+ patients: a randomized controlled trial.
    Lalezari JP; Beal JA; Ruane PJ; Cohen CJ; Jacobson EL; Sundin D; Leong WP; Raffanti SP; Wheeler DA; Anderson RD; Keiser P; Schrader SR; Goodgame JC; Steinhart CR; Murphy RL; Wolin MJ; Smith KA
    HIV Clin Trials; 2000; 1(3):1-15. PubMed ID: 11590500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy.
    Wang C; Vlahov D; Galai N; Bareta J; Strathdee SA; Nelson KE; Sterling TR
    J Infect Dis; 2004 Sep; 190(6):1046-54. PubMed ID: 15319852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term highly active antiretroviral therapy in chronic HIV-1 infection: evidence for reconstitution of antiviral immunity.
    Jansen CA; Piriou E; De Cuyper IM; van Dort K; Lange JM; Miedema F; van Baarle D
    Antivir Ther; 2006; 11(1):105-16. PubMed ID: 16518966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients].
    Li H; Zheng YH; Shen Z; Liu M; Liu C; He Y; Chen J; Ou QY; Huang ZL
    Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(42):2973-6. PubMed ID: 18261327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A study of the safety and survival of the adoptive transfer of genetically marked syngeneic lymphocytes in HIV-infected identical twins.
    Walker R; Blaese RM; Carter CS; Chang L; Klein H; Lane HC; Leitman SF; Mullen CA; Larson M
    Hum Gene Ther; 1993 Oct; 4(5):659-80. PubMed ID: 8280803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunologic features of HIV-1-infected women on HAART at delivery.
    Ono E; Dos Santos AM; Machado DM; Succi RC; Amed AM; Salomão R; Kallás EG; de Moraes-Pinto MI
    Cytometry B Clin Cytom; 2008 Jul; 74(4):236-43. PubMed ID: 18393385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.